Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 8/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631836 | 0.90 | DRD2 (0.34) | TDO2DRD2BRD3HTR2AHTR7 | |
| SCHEMBL12329636 | 0.87 | KMT2A (0.42) | HTR2A | |
| SCHEMBL2622086 | 0.86 | TDO2 (0.34) | TDO2DRD2BRD3HTR2AHTR7 | |
| SCHEMBL13448836 | 0.85 | BRD3 (0.39) | TDO2DRD2BRD3HTR2AHTR7 | |
| SCHEMBL2115303 | 0.83 | TGM2 (0.41) | GPR119ALDH1A1 | |
| SCHEMBL12329378 | 0.82 | CYP1A2 (0.35) | TDO2BRD3HTR2A | |
| SCHEMBL817916 | 0.80 | CNR2 (0.36) | TDO2DRD2BRD3HTR2AHTR7 | |
| SCHEMBL2452133 | 0.78 | BRD3 (0.41) | TDO2DRD2BRD3HTR2AHTR7 | |
| SCHEMBL374903 | 0.77 | GPR84 (0.40) | TDO2DRD2BRD3HTR2AHTR7 | |
| SCHEMBL12329376 | 0.77 | KMT2A (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | TDO2 4692/4885DRD2 4857/4885BRD3 992/4885 |
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | TDO2 4692/4885DRD2 4857/4885BRD3 992/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | TDO2 4692/4885DRD2 4857/4885BRD3 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.